Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Shares Sold by Wetherby Asset Management Inc.

Wetherby Asset Management Inc. lowered its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 5.2% during the second quarter, Holdings Channel reports. The firm owned 10,801 shares of the biopharmaceutical company’s stock after selling 597 shares during the period. Wetherby Asset Management Inc.’s holdings in Alexion Pharmaceuticals were worth $1,314,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in ALXN. Canada Pension Plan Investment Board raised its stake in Alexion Pharmaceuticals by 35.9% in the second quarter. Canada Pension Plan Investment Board now owns 351,796 shares of the biopharmaceutical company’s stock worth $42,803,000 after buying an additional 92,866 shares during the period. Cigna Investments Inc. New raised its stake in Alexion Pharmaceuticals by 21.0% in the second quarter. Cigna Investments Inc. New now owns 11,150 shares of the biopharmaceutical company’s stock worth $1,357,000 after buying an additional 1,936 shares during the period. Global X Management Co. LLC raised its stake in Alexion Pharmaceuticals by 37.5% in the second quarter. Global X Management Co. LLC now owns 2,703 shares of the biopharmaceutical company’s stock worth $329,000 after buying an additional 737 shares during the period. Seven Bridges Advisors LLC raised its stake in Alexion Pharmaceuticals by 2.1% in the second quarter. Seven Bridges Advisors LLC now owns 2,638 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 53 shares during the period. Finally, TD Asset Management Inc. raised its stake in Alexion Pharmaceuticals by 10.3% in the second quarter. TD Asset Management Inc. now owns 397,087 shares of the biopharmaceutical company’s stock worth $48,314,000 after buying an additional 37,028 shares during the period. Institutional investors and hedge funds own 95.14% of the company’s stock.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at 136.85 on Thursday. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $145.42. The company’s 50-day moving average price is $128.92 and its 200 day moving average price is $122.85. The firm has a market cap of $30.54 billion, a P/E ratio of 59.35 and a beta of 1.41.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.48. The business had revenue of $912 million for the quarter, compared to analysts’ expectations of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The business’s quarterly revenue was up 21.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.13 earnings per share. On average, equities analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.60 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Shares Sold by Wetherby Asset Management Inc.” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/2799652/alexion-pharmaceuticals-inc-nasdaqalxn-shares-sold-by-wetherby-asset-management-inc.html.

A number of research firms recently commented on ALXN. BidaskClub upgraded Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 5th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 price target on the stock in a research report on Wednesday, August 2nd. BMO Capital Markets restated an “outperform” rating and set a $168.00 price target (up from $159.00) on shares of Alexion Pharmaceuticals in a research report on Friday, July 28th. Leerink Swann increased their price target on Alexion Pharmaceuticals from $136.00 to $170.00 and gave the stock an “outperform” rating in a research report on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. upgraded Alexion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $175.00 price target on the stock in a research report on Friday, July 28th. Five investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and three have given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $156.89.

In related news, Director Bros. Advisors Lp Baker acquired 660,779 shares of the business’s stock in a transaction dated Thursday, June 15th. The shares were bought at an average price of $117.33 per share, with a total value of $77,529,200.07. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Ann M. Veneman sold 700 shares of the stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $137.74, for a total transaction of $96,418.00. Following the transaction, the director now directly owns 6,315 shares in the company, valued at approximately $869,828.10. The disclosure for this sale can be found here. Insiders have acquired 2,019,734 shares of company stock worth $235,606,846 in the last ninety days. Insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.